Scienture Holdings Enters New Agreement, Terminates Old One

Ticker: SCNX · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1382574

Scienture Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyScienture Holdings, Inc. (SCNX)
Form Type8-K
Filed DateOct 16, 2025
Risk Levelmedium
Pages6
Reading Time7 min
Key Dollar Amounts$0.00001, $2,000,000, $2,656,250, $791.67, $1,069.44
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, agreement-termination, financial-obligation

TL;DR

Scienture Holdings just signed a new deal and ditched an old one. Big changes ahead.

AI Summary

On October 10, 2025, Scienture Holdings, Inc. entered into a material definitive agreement and simultaneously terminated a prior material definitive agreement. The company also became subject to a direct financial obligation or an off-balance sheet arrangement. Specific details regarding the nature of these agreements and obligations were not provided in this filing.

Why It Matters

This filing indicates a significant shift in Scienture Holdings' contractual relationships, potentially impacting its financial obligations and strategic direction.

Risk Assessment

Risk Level: medium — The entry into and termination of material definitive agreements, along with new financial obligations, suggests significant operational or financial changes that warrant attention.

Key Players & Entities

  • Scienture Holdings, Inc. (company) — Registrant
  • October 10, 2025 (date) — Date of earliest event reported
  • TRxADE HEALTH, INC (company) — Former company name
  • TRXADE GROUP, INC. (company) — Former company name
  • XCELLINK INTERNATIONAL INC. (company) — Former company name

FAQ

What is the nature of the material definitive agreement entered into by Scienture Holdings, Inc. on October 10, 2025?

The filing states that Scienture Holdings, Inc. entered into a material definitive agreement on October 10, 2025, but does not provide specific details about its nature.

What was the previous material definitive agreement that Scienture Holdings, Inc. terminated?

The filing indicates the termination of a material definitive agreement on October 10, 2025, but does not specify which agreement it was.

What direct financial obligation or off-balance sheet arrangement is Scienture Holdings, Inc. now subject to?

The filing reports that Scienture Holdings, Inc. is now subject to a direct financial obligation or an off-balance sheet arrangement, but does not provide further details.

When was Scienture Holdings, Inc. formerly known as TRxADE HEALTH, INC?

Scienture Holdings, Inc. was formerly known as TRxADE HEALTH, INC. following a name change on June 2, 2021.

What is the Standard Industrial Classification code for Scienture Holdings, Inc.?

The Standard Industrial Classification code for Scienture Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,719 words · 7 min read · ~6 pages · Grade level 11.4 · Accepted 2025-10-16 17:00:37

Key Financial Figures

  • $0.00001 — ch registered Common Stock, par value $0.00001 per share SCNX The Nasdaq Stock Mar
  • $2,000,000 — Loan ") involving a principal amount of $2,000,000. The original maturity of the NVK Loan
  • $2,656,250 — nclusive of principal and interest, was $2,656,250 (the " Outstanding Balance "). In the e
  • $791.67 — Outstanding Balance plus an additional $791.67 per day (or $1,069.44 per day if there
  • $1,069.44 — plus an additional $791.67 per day (or $1,069.44 per day if there is an Event of Default
  • $25,000 — d to (i) pay NVK a fee in the amount of $25,000 plus any associated legal fees; (ii) pa
  • $3,911,111.11 — missory note in the principal amount of $3,911,111.11 (the " Note "). The Note carries an ori
  • $391,111.11 — e carries an original issue discount of $391,111.11. The Company agreed to pay $20,000 to t
  • $20,000 — $391,111.11. The Company agreed to pay $20,000 to the Lender to cover the Lender's tra
  • $3,500,000 — n the Company receiving net proceeds of $3,500,000. Upon receipt of the net proceeds, the

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCIENTURE HOLDINGS, INC. By: /s/ Dr. Narasimhan Mani Dr. Narasimhan Mani Co-Chief Executive Officer Date: October 16, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.